

2022 Insurer Reporting
Most Prescribed Drugs

Drug	Class	Prescriptions
COVID-19 (SARS-CoV-2) mRNA Virus Vaccine <i>Moderna and Pfizer-BioNTech</i>	Vaccines	537,155
Influenza Virus Vaccine <i>Includes these brand names: Afluria, Fluarix, Flulaval, Fluzone, Flu</i>	Vaccines	231,714
Atorvastatin Calcium <i>Includes generics and these brand names: Lipitor</i>	Antihyperlipidemics	194,032
Levothyroxine Sodium <i>Includes generics and these brand names: Euthyrox, Levoxyl, Synt</i>	Thyroid Agents	191,047
Lisinopril	Antihypertensives	172,584
Bupropion HCl <i>Includes generics and these brand names: Wellbutrin</i>	Antidepressants	144,690
Metformin HCl	Antidiabetics	140,073
Amphetamine-Dextroamphetamine <i>Includes generics and these brand names: Adderall, Mydayis</i>	ADHD/Anti-Narcolepsy/ Anti-Obesity/Anorexiant	130,632
Escitalopram Oxalate <i>Includes generics and these brand names: Lexapro</i>	Antidepressants	117,177
Losartan Potassium	Antihypertensives	112,056

2022 insurer report information

<https://dfr.oregon.gov/drugtransparency/Documents/Prescription-Drug-Price-Transparency-Annual-Report-2022.pdf#page=41>

2022 Insurer Reporting
Most Costly Drugs

Drug	Class	Total Spent
Adalimumab <i>Brand name: Humira</i>	Analgesics - Anti-Inflammatory	\$76,966,470
Ustekinumab <i>Brand name: Stelara</i>	Dermatologicals	\$35,999,195
Etanercept <i>Brand name: Enbrel</i>	Analgesics - Anti-Inflammatory	\$28,675,010
Bictegravir-Emtricitabine-Tenofovir Alafenamide Fum <i>Brand name: Biktarvy</i>	Antivirals	\$23,245,660
COVID-19 (SARS-CoV-2) mRNA Virus Vaccine <i>Moderna and Pfizer-BioNTech</i>	Vaccines	\$20,679,117
Elexacaftor-Tezacaftor-Ivacaftor <i>Brand name: Trikafta</i>	Respiratory Agents	\$17,964,545
Secukinumab <i>Brand name: Cosentyx</i>	Dermatologicals	\$17,770,873
Pembrolizumab <i>Brand name: Keytruda</i>	Antineoplastics and Adjunctive Therapies	\$16,463,259
Vedolizumab <i>Brand name: Entyvio</i>	Gastrointestinal Agents	\$14,872,464
Ocrelizumab <i>Brand name: Ocrevus</i>	Psychotherapeutic and Neurological Agents	\$11,115,070

2022 insurer report information

<https://dfr.oregon.gov/drugtransparency/Documents/Prescription-Drug-Price-Transparency-Annual-Report-2022.pdf#page=41>

2022 Insurer Reporting
 Drugs with greatest increase in plan spending

Drug	Class	Year-Over-Year Increase
COVID-19 (SARS-CoV-2) mRNA Virus Vaccine <i>Moderna and Pfizer-BioNTech</i>	Vaccines	\$17,866,475
Ustekinumab <i>Brand name: Stelara</i>	Dermatologicals	\$7,623,454
Elexacaftor-Tezacaftor-Ivacaftor <i>Brand name: Trikafta</i>	Respiratory Agents	\$4,906,302
Semaglutide <i>Includes these brand names: Ozempic, Rybelsus, Wegovy</i>	Antidiabetics	\$3,092,976
Risankizumab-rzaa <i>Brand name: Skyrizi</i>	Dermatologicals	\$3,088,360
Pembrolizumab <i>Brand name: Keytruda</i>	Antineoplastics and Adjunctive Therapies	\$3,072,226
Ocrelizumab <i>Brand name: Ocrevus</i>	Psychotherapeutic and Neurological Agents	\$3,046,577
Emtricitabine-Tenofovir Disoproxil Fumarate <i>Includes generics and these brand names: Truvada</i>	Antivirals	\$2,848,130
Pertuzumab <i>Brand name: Perjeta</i>	Antineoplastics and Adjunctive Therapies	\$2,771,539
Lenalidomide <i>Brand name: Revlimid</i>	Immunomodulators	\$2,628,811

2022 insurer report information
<https://dfr.oregon.gov/drugtransparency/Documents/Prescription-Drug-Price-Transparency-Annual-Report-2022.pdf#page=41>